Letter from R B Christie, Director of Clinical Sciences at Revlon Health Care UK Limited, to the Adverse Reactions Monitoring Unit at the Committee on Safety of Medicines, regarding an enclosure of a report on the suspected toxicity or side effects relating to areport of Hepatitis B